foxo4-dri human trial peptide senolytic inhibitors targeting FOXO4-p53 interactions and inducing senescent cancer cell-specific apoptosis FOXO4-DRI 10mg vial foxo4-dri senolytic peptide human trial

Produced using quality-focused manufacturing processes, this research blend is designed to provide consistency, reliability, and traceability for professional laboratory applications

This is the more sensitive marker for early deficiency

PubChem Reference: View compound profile on NIH PubChem Key Characteristics MOLECULAR PROFILE Formula: C 62 H 98 N 16 O 22 Weight: 1,419.53 g/mol CAS: 137525-51-0 Sequence: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val PHYSICAL PROPERTIES Form: White to off-white lyophilized powder Solubility: Readily dissolves in water Stability: Stable across various pH conditions Storage: Keep refrigerated 3646 F (28 C) Related products Thymulin $45.00 $65.00Price range: $45.00 through $65.00 TB-500 $60.00 $90.00Price range: $60.00 through $90.00 CJC-1295 $60.00 $95.00Price range: $60.00 through $95.00

Administration Typical delivery methods are subcutaneous or intramuscular injection, oral formulations, and nasal sprays